Pfizer
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.50 | 4 |
| infectiousDisease | ×1.50 | 4 |
| gastroenterology | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.50 | 6 |
| phase 1 | ×1.16 | 4 |
| phase 2 | ×1.50 | 4 |
Strategy profile
Based on 1 disclosed transaction, Pfizer concentrates its licensing activity in Hematology. Pfizer pays a 1.50x premium over market median, with the strongest premiums in Oncology (1.50x). Their most common deal structure is Acquisition, with an average disclosed value of $2.3B. Most recent activity: 2021.
Premium by therapeutic area
How Pfizer pays relative to peer medians in each TA
Pipeline coverage & gaps
Pfizer has disclosed activity in 3 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 1 | $2.3B | $2.3B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2021 | TTI-622 and TTI-621 | Trillium Therapeutics | AML, MDS | phase_1 | $2.3B | $2.3B |
How this is computed
For each Pfizer deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 18 disclosed deal premiums vs. peer medians. Raw premium 1.939, clamped to [0.7, 1.5].